Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab for the Treatment of Soft Tissue Sarcoma


3rd Orphan Drug designation for Toripalimab 3rd Orphan Drug designation for Toripalimab

Here is the original post:
Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab for the Treatment of Soft Tissue Sarcoma

Related Posts